Patient Perspectives on Palliative Care in Pulmonary Arterial Hypertension in the United States Authors: Karim El‐Kersh, Rebecca Crawford, Hilary DuBrock, Peter Classi, Phuong Phan, Lori McLeod, Benjamin Wu, Denise Sese Published: 2026 ABSTRACT ABSTRACTPalliative care can be offered concurrently as a treatment option to patients with pulmonary arterial hypertension (PAH) to relieve symptoms and improve quality of life. However, it is infrequently used and is associated with misconceptions. Limited studies have reported patients' perspectives of palliative care as a treatment option for PAH. We conducted a web‐based survey, informed by a brief targeted literature review and input from patients and clinicians, which was completed by adults (≥ 18 years) in the United States (US) with self‐reported PAH. Patients reported demographic and disease variables and their perspectives and experiences with palliative care. Patients self‐reported their Pulmonary Hypertension Functional Class Self‐Report class, EmPHasis‐10, and 6‐min walk test. A total of 200 respondents (86.5% female; mean age 58.5 years) from 42 US states completed the survey between 19 September and 3 October 2023. Most respondents described palliative care as “end‐of‐life care” (n = 43, 25.7%) and associated it with the need for extra support (n = 111, 55.5%). Many respondents (n = 171, 85.5%) had not discussed palliative care services, nor had a palliative care consultation with their healthcare provider (HCP); most had not been offered a consultation (n = 109/171, 63.7%). Despite this low frequency of discussions, respondents reported feeling comfortable discussing palliative care with their HCPs (n = 177, 88.5%). The survey results demonstrated that these patients with PAH had limited experiences with palliative care, where palliative care was frequently subject to misinterpretation. These findings emphasize the need for proactive engagement between patients and HCPs to ensure palliative care is optimally used and understood. Abbreviations 6‐min walk test Healthcare professional Heart failure with preserved ejection fraction Health‐related quality of life Local Social Inequity Not applicable Pulmonary arterial hypertension Palliative care Pulmonary hypertension Pulmonary Hypertension Association Registry Pulmonary Hypertension Functional Class Self‐Report Standard deviation United States. Pulmonary arterial hypertension (PAH) is a chronic and progressive subtype of pulmonary hypertension (PH), resulting from restricted flow through the pulmonary arterial circulation [1, 2, 3]. It can lead to increased pulmonary vascular resistance and right heart failure, and if left untreated, death [1, 2, 3, 4, 5, 6]. Common symptoms include dyspnea, fatigue, edema, heart palpitations, lightheadedness, and syncope [3]. Additionally, patients suffer with psychosocial symptoms, including depression, anxiety, and stress, which collectively impair health‐related quality of life (HRQOL) [7, 8, 9, 10]. Although pharmacological products are the mainstay of treatment, palliative care—which aims to relieve physical and emotional symptoms of patients with serious illnesses like PAH—can be provided concurrently [6, 11, 12]. The goal of palliative care is to improve the HRQOL of both the patient and their families and can be provided in either an inpatient or outpatient setting [6, 11, 12]. However, despite these benefits, it is frequently underused; referral in the inpatient setting was reported in only 2.2% of patients between 2001 and 2017 [6, 13]. The lack of access to palliative care in some healthcare systems restricts the availability of treatment to patients [14], and the misconception surrounding the use of palliative care is also a barrier that limits its use. Additional barriers include misconceptions around the utility of palliative care, including the association with end‐of‐life care, as well as some physicians believing that patients cannot receive both palliative care and another PAH therapy simultaneously [6, 14, 15]. Patients who experience greater symptom burden with PAH have been reported to have more negative emotional reactions towards palliative care; their worsening physical condition may heighten fears of death, loss of control, and hopelessness, which is potentially exacerbated by misconception that palliative care is an admission of defeat rather than a supportive measure [16]. Nevertheless, evidence suggests that despite this misconception, some patients may still be willing to discuss it as a treatment option with their physician [17, 18]. Currently, only small, single center studies have assessed the patient perspective toward palliative care as a treatment option for PAH [16]; thus, the aim of the study was to conduct a larger, national study with a broad recruitment of patients with PAH to explore their current perspectives on palliative care. Methods Study Design This was a non‐interventional, cross‐sectional, web‐based survey of adult patients with self‐reported PAH in the United States (US). An electronic survey tool was developed comprising closed‐ended and 4 open‐ended questions on demographic and disease variables, palliative care perspectives and experience, and a standardized patient‐reported outcome instrument, EmPHasis‐10, an HRQOL prognostic marker in patients with PAH, predictive of mortality [19]. The survey content was informed by a brief targeted literature review on palliative care in PAH; 5 key publications were identified: Swetz et al. (2012) [18]; Anand et al. (2020) [13]; Constantine et al. (2021) [20]; Brown et al. (2023) [17]; and Rohlfing et al. (2023) [11]. Common themes that emerged from the selected publications included the low use of palliative care by patients with PAH as well as several misperceptions of palliative care (e.g., patients need to be very sick to receive palliative care, hospice care is equivalent to palliative care, and receipt of palliative care would stop pharmacological treatment of PAH). The survey underwent an iterative process, including review and input from clinicians and patients with PAH, and was developed in US English. Patients' functional class was self‐reported vita the Pulmonary Hypertension Functional Class Self‐Report (PH‐FC‐SR), a patient‐reported version of the World Health Organization functional classification measure, to evaluate symptoms and physical activity impacts relevant to patients [21]. Patients' HRQOL was assessed using EmPHasis‐10, which comprises 10 items that capture PH‐related symptoms, emotional/psychological impacts, and functional limitations [22]. A semantic 6‐point scale (0–5) was used for EmPHasis‐10, with a total maximum score of 50; higher scores correspond to worse quality of life/symptom burden. Respondents were asked to recall the results of their last 6‐min walk test (6MWT) [23], their PAH risk status [24], and whether they were currently enrolled in the Pulmonary Hypertension Association Registry (PHAR). Participants' zip codes were used to derive RTI Rarity Local Social Inequity (LSI) scores, which assess community‐level risks associated with various health outcomes. The RTI Rarity™ project, developed by RTI International, uses artificial intelligence and machine learning to analyze local social determinants of health at the neighborhood level across the US. The RTI Rarity risk score ranges from 0 to 1, with higher values corresponding to greater social risk and a more socially vulnerable area. RTI's institutional review board (STUDY00022600) reviewed and approved this study. Study Population Respondents included adults aged ≥ 18 years based in the US, with a self‐reported diagnosis of PAH. All participants were required to speak and comprehend the web‐based survey conducted in English and provide electronic consent. Participants were recruited via a US‐based PAH patient advocacy organization: the Pulmonary Hypertension Association. Analyses Quantitative analysis of closed‐ended question data was descriptive with no inferential statistical tests performed and was conducted using Microsoft Excel 2013 (Microsoft Corporation; Redmond, Washington). Data from 200 participants who completed the survey were analyzed as observed, with no imputation of missing data, except in the case of EmPHasis‐10, for which missing data was handled according to its scoring guidelines. EmPHasis‐10 was scored following its standardized scoring guidelines, which included the treatment of individual item non‐response. A qualitative description approach was used for the analysis of the data derived from the open‐ended questions and for the analysis of the open text responses to the “other” category for the close‐ended questions, where appropriate. Information on individuals' experiences in relation to a specific topic was collected to describe what respondents say, rather than to extrapolate or make conceptual inferences [25, 26]. Results Participant Characteristics Overall, 200 respondents from 42 US states completed the survey between 19 September and 3 October 2023. Most respondents were female (n = 173, 86.5%), identified as White (n = 164, 82.0%), and had a mean (standard deviation [SD]) age of 58.5 (14.3) years (Table 1). Most respondents had achieved at least some college education or higher (n = 180, 90.0%), and approximately half of the respondents were married, living as married, or in a civil partnership (n = 102, 51.0%); the other half were single, divorced, separated, or widowed (n = 96, 48.0%). Respondents had a mean (SD) RTI Rarity LSI score of 0.5 (0.3); the distribution of RTI Rarity LSI scores revealed respondents to be diverse in terms of general health equity factors (Figure 1). Table 1Demographic characteristics.Demographic characteristicsOverall respondents (N = 200)Gender, n (%)Female173 (86.5)Male27 (13.5)Age, yearsMean (SD); n 58.5 (14.3); 200Median (quartile 1, quartile 3)61.0 (47.0, 69.0)Min, max23.0, 87.0Race, n (%)African American or Black14 (7.0)Alaska Native, American Indian, Native American5 (2.5)Asian7 (3.5)Hispanic, Latin American, or Latinx14 (7.0)Native Hawaiian or Pacific Islander1 (0.5)White164 (82.0)A race or ethnicity not listed2 (1.0)Relationship status, n (%)a Married/living as married/civil partnership102 (51.0)Single/divorced/separated/widowed96 (48.0)Living situation, n (%)a Live with partner and/or immediate family/other people142 (71.0)Live alone52 (26.0)Other4 (2.0)Education level, n (%)High school or less19 (9.5)College or some college134 (67.0)Advanced degree or higher46 (23.0)Rarity social risk score, mean (SD); n 0.5 (0.3); 197 Note: Percentages are based on non‐missing data.Abbreviations: max, maximum; min, minimum; SD, standard deviation. a Percentages do not total 100% as some respondents preferred not to answer.John Wiley & Sons, Ltd. Demographic characteristics. Note: Percentages are based on non‐missing data. Abbreviations: max, maximum; min, minimum; SD, standard deviation. Percentages do not total 100% as some respondents preferred not to answer. Population Distribution of RTI Rarity LSI Scores. LSI, local social inequity; Num, number; Obs, observations; Q1,quartile 1; Q3, quartile 3. The most common PAH etiology was idiopathic PAH (n = 71, 35.5%) or type unspecified (n = 69, 34.5%) (Table 2). Approximately 46.0% (n = 92) of respondents recalled that they had never discussed their last PAH risk status score with their doctor, and a further 11.0% (n = 22) could not remember their last score. Distribution of self‐reported PH‐FC‐SR scores indicated respondent diversity in terms of disease severity: Class I (n = 33, 16.5%), Class II (n = 83, 41.5%), Class III (n = 71, 35.5%), or Class IV (n = 13, 6.5%). Just over half of respondents (n = 79, 54.0%) self‐reported that their general health was excellent, very good, or good. Only 16 respondents (8.0%) reported no other diagnosed health conditions. Overall, approximately 64% of respondents (n = 127) were on dual or triple therapy. Table 2Clinical characteristics.Clinical characteristicsOverall respondents (N = 200)PAH etiology, n (%)Idiopathic PAH (unknown cause)71 (35.5)Heritable PAH4 (2.0)Drug and toxin induced PAH4 (2.0)PAH associated with connective tissue disease30 (15.0)PAH associated with HIV infection3 (1.5)PAH associated with portal hypertension (Liver disease associated with increased pressure in the liver)2 (1.0)PAH associated with congenital heart diseases17 (8.5)PAH (type unspecified)69 (34.5)Length of PAH diagnosis, yearsMean (SD)9.6 (8.8)Median (quartile 1, quartile 3)7.9 (2.5, 13.3)Min, max0.3, 64.5Self‐reported last PAH risk status score, n (%)Low31 (15.5)Intermediate34 (17.0)High21 (10.5)Never discussed with doctor92 (46.0)Don't remember22 (11.0)Self‐reported PH‐FC‐SR, n (%)Class I33 (16.5)Class II83 (41.5)Class III71 (35.5)Class IV13 (6.5)Self‐reported general health, n (%)Excellent4 (2.0)Very good32 (16.0)Good72 (36.0)Fair73 (36.5)Poor19 (9.5)Severity of PAH symptoms past 7 days, n (%)No symptoms14 (7.0)Mild80 (40.0)Moderate89 (44.5)Severe15 (7.5)Very severe2 (1.0)Most bothersome PAH symptoms past 7 days, n (%) n = 197Shortness of breath76 (38.6)Tiredness (fatigue)83 (42.1)Dizziness7 (3.6)Chest pain4 (2.0)Racing heart (heart palpitations)6 (3.0)Swelling (edema) in the legs, ankles, feet or stomach (abdomen)21 (10.7)Missing3 (1.5)PAH impact on life past 7 days, n (%)Not at all13 (6.5)A little95 (47.5)Quite a lot73 (36.5)A lot19 (9.5)Current treatment, n (%)a n = 198Diuretics123 (62.1)Oxygen85 (42.9)Tadalafil84 (42.4)Ambrisentan59 (29.8)Macitentan53 (26.8)Blood thinners48 (24.2)Sildenafil38 (19.2)Treprostinil (parenteral)32 (16.2)Selexipag29 (14.6)Calcium channel blockers26 (13.1)Riociguat26 (13.1)Treprostinil (inhalation solution)18 (9.1)Treprostinil (oral)9 (4.5)Digoxin8 (4.0)Bosentan6 (3.0)Epoprostenol6 (3.0)Investigational drug/therapy2 (1.0)Other8 (4.0)Iloprost1 (0.5)Not reported2 (1.0)Therapy/regimen classification n = 198Monotherapy45 (22.7)Dual therapy67 (33.8)Triple therapy60 (30.3)No PAH‐specific medication26 (13.1)PHAR enrolled, n (%)Yes43 (21.5)No59 (29.5)Don't remember98 (49.0)Reported health condition, n (%)Yes184 (92.0)No16 (8.0)Abbreviations: max, maximum; min, minimum; PAH, pulmonary arterial hypertension; PHAR, pulmonary hypertension association registry; PH‐FC‐SR, pulmonary hypertension functional classification Self‐Report; SD, standard deviation. a The total percentage exceeds 100% as respondents could report more than 1 type of treatment.John Wiley & Sons, Ltd. Clinical characteristics. Abbreviations: max, maximum; min, minimum; PAH, pulmonary arterial hypertension; PHAR, pulmonary hypertension association registry; PH‐FC‐SR, pulmonary hypertension functional classification Self‐Report; SD, standard deviation. The total percentage exceeds 100% as respondents could report more than 1 type of treatment. Most respondents reported that in the 7 days prior to completing the survey, they had experienced symptoms of either mild (n = 80, 40%) or moderate (n = 89, 44.5%) severity; fatigue (n = 83, 42.1%), shortness of breath (n = 76, 38.6%), and edema (n = 21, 10.7%) were reported as the most bothersome PAH symptoms experienced. The majority of respondents (n = 187, 93.5%) reported that their PAH had impacted their life to some degree in the 7 days prior to survey completion. Only 21.5% (n = 43) of respondents could recall that they were currently enrolled in PHAR, compared with nearly half (n = 98, 49%) who could not remember if they were currently enrolled. The top 3 reported treatments currently used by respondents included diuretics (n = 123, 62.1%), oxygen therapy (n = 85, 42.9%), and tadalafil (n = 84, 42.4%). The most common PAH‐specific medication class was phosphodiesterase‐5 inhibitors and soluble guanylate cyclase stimulators (n = 148, 74.7%) (e‐Table 1); one‐fifth of patients were on parenteral prostacyclin therapy (n = 38, 19.2%). One‐third of patients were on dual therapy (n = 67, 33.8%), while nearly another third of patients were on triple therapy (n = 60, 30.3%). 6‐min Walk Test (6MWT) and EmPHasis‐10 Descriptive statistics for respondents' 6MWT and EmPHasis‐10 scores, stratified by self‐reported PH‐FC‐SR Class, revealed respondents' global perspective on the aspects of their care that are most important to them. Less than 50% of respondents recalled their last 6MWT score (n = 90, 45.0%). 1 The mean (SD) respondent‐recalled 6MWT was 347.5 (±178.8) meters (mean [SD] of PH‐FC‐SR classes I‐IV: 526.0 [106.6], 381.2 [157.8], 256.3 [153.4], and 182.2 [132.7], respectively), indicative of moderate disease severity. The stratification of respondent‐recalled 6MWT by self‐reported PH‐FC‐SR class highlights the progressive decline in walking ability for the respondents in the higher PH‐FC‐SR classes (Figure 2). The EmPHasis‐10 mean (SD) (27.1 [10.8]) (mean [SD] of PH‐FC‐SR classes I‐IV: 15.5 [11.3], 25.6 [8.5], 32.6 [7.8], and 36.2 [8.7], respectively) indicated moderate impairment of respondents' HRQOL and symptom burden due to PAH. The stratification of EmPHasis‐10 scores by PH‐FC‐SR class revealed that as PAH severity increases (i.e., from PH‐FC‐SR Class I to IV), mean EmPHasis‐10 scores also increase, highlighting that respondents with more severe PAH experience worse HRQOL and greater symptom burden. Self‐Reported 6MWT Groups by PH‐FC‐SR. PH‐FC‐SR = Pulmonary Hypertension Functional Class Self‐Report; 6MWD = 6‐min walking distance; 6MWT = 6‐min walk test. Notes: One participant reported a 6MWD of 0 meters; no additional information was collected to clarify whether this reflected the need for full assistance or inability to ambulate. Therefore, the score was interpreted as an inability to perform the test and treated as missing data rather than a measured value. Consequently, this participant was excluded from the 6MWD analysis dataset. Perspectives on Palliative Care Knowledge and Interpretation of Palliative Care Overall, most respondents (n = 167, 83.5%) provided their own definition of palliative care; the most frequent interpretations described palliative care as either “end‐of‐life care” (n = 43, 25.7%), “comfort care” (n = 22, 13.2%), or support (n = 16, 9.6%) (Table 3). Other respondent descriptions included specialized care, care for chronic/serious/terminal conditions, and care designed to improve/maintain HRQOL and manage symptoms. The remaining 33 respondents reported that they had never heard of palliative care (n = 27, 13.5%) or opted not to answer (n = 6, 3.0%).To me it means your care is mainly to keep you as comfortable as possible while knowing your health will not improve and your death will be, if the next step. Providing comfort (physical, emotional and medically) to a chronically ill patient toward the end of their life by recognizing their quality of life. Not utilizing often painful interventions, that only prolong suffering without much hope of extending functional, quality of life. Care designed to make you comfortable while allowing your disease to progress. Focus on comfort versus heroics. To me it means your care is mainly to keep you as comfortable as possible while knowing your health will not improve and your death will be, if the next step. Providing comfort (physical, emotional and medically) to a chronically ill patient toward the end of their life by recognizing their quality of life. Not utilizing often painful interventions, that only prolong suffering without much hope of extending functional, quality of life. Care designed to make you comfortable while allowing your disease to progress. Focus on comfort versus heroics. Table 3Self‐reported terminology for palliative care.Self‐reported definition (N = 167) n (%)End‐of‐life care43 (25.7)Comfort care (not including end‐of‐life)22 (13.2)Specialized care15 (9.0)Support16 (9.6)Care for chronic/serious/terminal condition14 (8.4)Care designed to improve/maintain HRQOL10 (6.0)Manage symptoms10 (6.0)Other37 (22.3)Abbreviation: HRQOL, health‐related quality of life.John Wiley & Sons, Ltd. Self‐reported terminology for palliative care. Abbreviation: HRQOL, health‐related quality of life. For the 167 respondents who were familiar with palliative care, the most common source of information pertaining to palliative care services identified by respondents was provided by hospital medical staff (doctors, nurses, allied health workers) (n = 39/167, 23.4%), the internet/social media (online patient forums) (n = 32/167, 19.2%), and family/friends (n = 32/167, 19.2%). Nearly 25% of respondents reported that they had not received any information about palliative care services or were not sure of the information source (n = 41/167, 24.6%). Over 50% of respondents associated palliative care with the following statements: the need for extra support (n = 111, 55.5%), that more support would result in improved well‐being (n = 110, 55.0%), and that the patient's PAH is a terminal, incurable disease (n = 107, 53.5%) (e‐Table 2). Palliative Care Experience and Discussions With Healthcare Professionals (HCPs) Most respondents (n = 171) had not discussed palliative care services nor had a consultation with their HCP about palliative care; almost two‐thirds of these respondents reported that a palliative care consultation had not been offered (n = 109/171, 63.7%), or they were not “sick enough” for palliative care (n = 80, 46.8%) (Figure 3; Table 4). Despite this, the majority (n = 177, 88.5%) stated they would feel comfortable discussing palliative care with their HCPs. For the 15 respondents who indicated that they would not feel comfortable discussing palliative care with their HCP, several themes emerged: preferring not to think about palliative care or not feeling mentally ready to think about palliative care (n = 4), lack of knowledge about palliative care (n = 3), and disease stability (i.e., palliative care not currently required) (n = 3). Palliative care discussions with HCPs engendered a range of emotions for respondents; feeling “anxious” (n = 85, 42.5%) and “hopeful” (n = 61, 30.5%) were the most frequently reported emotional impacts. Palliative Care Experience and Discussions With HCPs. HCP = healthcare provider; PC = palliative care. Table 4Discussion of palliative care with HCPs.Overall respondents (N = 200)PC consultation with HCP, n (%)Yes26 (13.0)No171 (85.5)Prefer not to answer3 (1.5)Comfortable discussing PC with HCP, n (%)Yes177 (88.5)No15 (7.5)Statement best describes absence of PC consultation with HCP, n (%) n = 171No one offered109 (63.7)I am too young for a palliative medicine11 (6.4)I am not “sick enough” for palliative care80 (46.8)My primary PAH physician was not agreeable to setting up a consult1 (0.6)The term “palliative” does not sound appealing6 (3.5)My medical providers may think I'm “giving up” and may not treat me as aggressively5 (2.9)My PAH medications (oral medications, infusions, inhalers, etc.) would stop if I received palliative care4 (2.3)Palliative medicine and hospice mean the same thing to me, and I am not ready for hospice20 (11.7)“End‐of‐life” care is not appropriate for my chronic condition17 (9.9)Other15 (8.8)Rationale for not feeling comfortable discussing PC with HCP n = 15Prefer not to think/not mentally ready to think about PC4Lack of knowledge about PC3Disease is stable, PC not required3Fear1Does not want HCP to think they are giving up1HCP is open to all options1No reason, just does not talk about PC1No response1Emotions experienced, n (%)Anxious85 (42.5)Hopeful61 (30.5)Comforted58 (29.0)Scared57 (28.5)Reassured56 (28.0)Stressed50 (25.0)Frightened37 (18.5)Secure28 (14.0)Hopeless16 (8.0)Other25 (12.5) Note: “Other” includes “Doing well on current treatment”; “Condition is currently stable/well managed”; “Still able to work”; “Never brought up topics”; “don't need it at the moment”; “Been receiving PC but not referred to as PC”; “Don't understand what PC is”; and “Unable to get Dr. to assist with PC.”Abbreviations: HCP, healthcare provider; PAH, pulmonary arterial hypertension; PC, palliative care.John Wiley & Sons, Ltd. Discussion of palliative care with HCPs. Note: “Other” includes “Doing well on current treatment”; “Condition is currently stable/well managed”; “Still able to work”; “Never brought up topics”; “don't need it at the moment”; “Been receiving PC but not referred to as PC”; “Don't understand what PC is”; and “Unable to get Dr. to assist with PC.” Abbreviations: HCP, healthcare provider; PAH, pulmonary arterial hypertension; PC, palliative care. Only 7.5% (n = 15) of respondents had received palliative care. The reasons for palliative care referral selected by respondents included symptom management (i.e., pain and shortness of breath), care discussion goals, and impaired quality of life. Eleven of these respondents reported positive experiences, including improved emotional/psychological well‐being.Absolutely WONDERFUL reduces my stress, listens to each symptom, and designs a plan to tackle the issue. Palliative care also keeps my PH doctor in the loop and vice‐versa. I don't know where I'd be now, if it wasn't for this amazing service. It was very positive and made a huge difference. I didn't want to live the way I was feeling but after seeing her and getting options, I feel 1,000% better and validated. Absolutely WONDERFUL reduces my stress, listens to each symptom, and designs a plan to tackle the issue. Palliative care also keeps my PH doctor in the loop and vice‐versa. I don't know where I'd be now, if it wasn't for this amazing service. It was very positive and made a huge difference. I didn't want to live the way I was feeling but after seeing her and getting options, I feel 1,000% better and validated. Palliative Care as a Support for Patients With PAH The key theme that emerged from respondents' responses to why someone with PAH would receive palliative care included the need for support (n = 78, 39.0%); specifically, support for self‐care, daily activities, emotional/psychological well‐being, and medical needs (Table 5). Additional themes that emerged included preparation for end of life, improved quality of life, and lack of treatment efficacy.This illness carries constant challenges. Even when managed in the best ways there are good days and bad days. Something as simple as a cold can feel terrifying. Having the options of extra care would have a tremendous effect on emotional and mental health. I think someone with a [sic] PAH would receive palliative care to help them keep control over their life during a serious, chronic disease, to help them maintain a more positive outlook, but mostly to keep control of some sort when it seems like everything is out of their control. This illness carries constant challenges. Even when managed in the best ways there are good days and bad days. Something as simple as a cold can feel terrifying. Having the options of extra care would have a tremendous effect on emotional and mental health. I think someone with a [sic] PAH would receive palliative care to help them keep control over their life during a serious, chronic disease, to help them maintain a more positive outlook, but mostly to keep control of some sort when it seems like everything is out of their control. Table 5Reasons why someone with PAH would receive palliative care.Theme (N = 200) n Support78End of life28Improve HRQOL24Medication/treatment ineffective20Disease progression14Don't know/not sure10Chronic/incurable condition11Exhausted all other options/treatments8Symptom management/control7Impact/decline in HRQOL8Symptom severity7Symptom worsening5Targeted care plan4Improve well‐being/feel better5Disease severity3Education/information3Symptom reduction3Maintain quality of life2Control condition2Disease stage/type2Burden on family2Other10Not relevant5Abbreviations: HRQOL, health‐related quality of life; PAH, pulmonary arterial hypertension.John Wiley & Sons, Ltd. Reasons why someone with PAH would receive palliative care. Abbreviations: HRQOL, health‐related quality of life; PAH, pulmonary arterial hypertension. Over 50% of respondents selected the response options “help me prepare for the future” (n = 109, 54.8%) and “provide emotional support” (n = 105, 52.8%) in terms of how palliative care could help them now in terms of their current PAH severity (e‐Table 3). Over a third of respondents also stated they would like palliative care help for daily activities and for managing symptoms, as well as to provide help for family and friends. Despite some variability in respondents' interpretation and experience of palliative care, the preferred term to describe palliative care voted for by more than half of the respondents was “supportive care” (n = 103, 51.8%), followed by “symptom management care” (n = 38, 19.1%), “palliative care” (n = 29, 14.6%), and “holistic care” (n = 18, 9.0%) and “other” (n = 9, 4.5%); not reported, (n = 1, 0.5%). Discussion This study provides insights into the current perspectives on palliative care among patients with PAH, including patients' interpretations, experiences, discussions with HCPs, and views on palliative care as a support for patients. The results provided emphasis on the importance of including patient‐reported outcomes in clinical practice for understanding patient experiences and preferences, guiding holistic treatment decisions, and enhancing patient‐centered care in PAH management. The majority of the respondents included in this survey were currently taking combination PAH‐specific therapy, consistent with current recommendations from the European Society of Cardiology and European Respiratory Society guidelines [27]. The high prevalence of combination PAH‐specific therapy among respondents underscores the advanced disease severity and associated symptom burden within this population. Given the complex treatment regimens and potential for significant adverse effects [28, 29], there is a clear role for early integration of palliative care to address physical symptoms, enhance quality of life, and support psychosocial needs. However, the most common self‐reported definition of palliative care by respondents was “end‐of‐life care” and was mainly associated with being an “additional support,” a key theme reported by respondents for the need for palliative care. These findings may explain why half of the respondents preferred the term “supportive care” to describe palliative care. Previous studies have also reported that patients negatively perceive palliative care as comparable with end‐of‐life care, equating it with hospice care, “giving up,” or “dying” [16, 17, 18]. Despite this, patients have been shown to be open to discussing palliative care with their physician despite these negative perceptions [17, 18]. These negative associations may be influenced by patients' limited understanding of palliative care or never having heard the term, which was the case for some respondents in this survey. However, when respondents were presented with the definition of palliative care, they became open to it as a treatment option, which may be a contributing factor to the misconception of palliative care. Collectively, these findings indicate that greater education and awareness of palliative care are needed to positively influence the patient perspective on palliative care. With regard to discussing palliative care with HCPs, most respondents had not discussed palliative care services, nor had they had a consultation with their HCP. In addition, the inability of nearly half of respondents to recall their enrollment in PHAR may indicate limited patient engagement or awareness regarding registry participation. This highlights potential areas for improving communication between HCPs and patients regarding the purpose and importance of PHAR. Indeed, there is no established clinical criteria for referral to palliative care for PAH patients; historically, palliative care has been reserved for the advanced stages of PH [13, 20]. In some cases, it is only administered at the end of a patient's life when a patient is significantly ill, resulting in the need for a longer hospital stay [11, 13]. This is partially due to physicians' association of palliative care with end‐of‐life care, despite the World Health Organization emphasizing the need for palliative care at the early stages of disease [11, 13, 30]. Therefore, untimely utilization of palliative care by physicians restricts the accessibility of it as a treatment option for patients with PAH. These associations may explain why some patients feel that they are not “sick enough” to receive palliative care—as reported by many respondents in this survey. Despite respondents self‐reporting good general health, many reported the presence of PAH symptoms and impaired HRQOL. Self‐reported physical symptoms associated with PAH in this study, like fatigue, have previously been documented in other PAH studies [21, 31]. Additionally, the respondent‐recalled 6MWT scores and results of the EmPHasis‐10 revealed that higher PH‐FC‐SR classifications are associated with greater impairment of walking and HRQOL. This trend was consistent with associations observed between 6MWT, EmPHasis‐10, and physician‐assessed World Health Organization functional classification [19]. Taken together, these findings support the potential utility of patient‐reported outcomes for remotely assessing PAH severity in settings where physician‐based evaluations are not feasible. This study directly collected information on patients' perspectives and experiences with palliative care in PAH at scale via a standardized approach. The results have highlighted areas for improvement in educating patients and HCPs about palliative care services, as well as the need for improvement in communication between patients and HCPs. However, study limitations should be considered, including the self‐selecting nature of the recruitment process and the patient self‐reported diagnosis and disease severity. Due to the topic of the survey, response bias—specifically social desirability bias—has the potential to affect the reliability of the data collected. However, the survey was anonymously completed, which may reduce social desirability bias. Notably, digital exclusion was a limitation because only patients with access to email and web‐based surveys were able to participate, as well as being required to be proficient in English. Furthermore, a mixture of close‐ended and open‐ended questions was included to capture nuanced experiences, but these may not fully capture nuanced patient knowledge and experiences associated with palliative care. Open‐ended questions were strategically selected to allow greater depth for respondent feedback on key areas of interest, and although the survey content underwent rigorous testing with HCPs and patients, it is possible that respondents who are less familiar with certain medical terminology may misunderstand or misinterpret questions. While the majority of our patients (64%) reported receiving double or triple combination therapy consistent with the management of group 1 PAH, it is possible that individuals from other groups, such as those with heart failure with preserved ejection fraction‐associated PH (HFpEF‐PH), may have also been included in this study. The findings from this survey suggest that respondents are aware of the benefit of palliative care as a resource to help manage their PAH. Although previous research has demonstrated that patients perceive palliative care as comparable with end‐of‐life care, this study suggests the understanding of palliative care by patients with PAH goes beyond the common misconception of perceiving it as only comparable with end‐of‐life care. This survey highlights the need for proactive engagement between patients and their HCPs to ensure palliative care is optimally used and understood by both HCP and patient to benefit patients' well‐being and ability to manage their PAH. Author Contributions Karim El‐Kersh, Rebecca Crawford, Hilary DuBrock, Peter Classi, Phuong Phan, Lori McLeod, Benjamin Wu, and Denise Sese each contributed substantially to the study design, data analysis and interpretation, and the writing or review of the manuscript. All authors had full access to the data in the study and all had final responsibility for the decision to publish the manuscript. Ethics Statement The patient‐reported outcome development study was reviewed by RTI International's institutional review board (IRB) and was designated as exempt from IRB oversight (STUDY00022600). All participants provided electronic informed consent before any study procedures. Participants could opt out of the survey if they were not interested in participating. Conflicts of Interest K.E.K. served as a consultant for United Therapeutics, J&J, and Merck. H.D. has received grant funding from Bayer Pharmaceuticals, has served on advisory boards for United Therapeutics, Merck & Co. Inc., and Johnson & Johnson, and has received consulting fees from Merck & Co. Inc., and Johnson & Johnson. P.C., P.P., and B.W. are or were employees of United Therapeutics, which funded this research, when this study was conducted. B.W. may hold shares and/or stock options in the company. R.C. and L.M. are full‐time employees of RTI Health Solutions, a subsidiary of RTI International, which was retained by United Therapeutics Corporation to conduct the research that is the subject of this manuscript. Their compensation is unconnected to the studies on which they work. D.S. served as a speaker for J&J and Merck and has served on advisory boards for J&J. Role of Sponsors Authors affiliated with United Therapeutics, the sponsor of this study, contributed to the design of the study, the collection and analysis of the data, and the preparation of the manuscript. Supporting information e‐Table 1. PAH Medication Classification. e‐Table 2. Statements Associated With PC. e‐Table 3. Perceived Help That Palliative Care Could Provide Now.